1.Sales and profit
See section β- Alx Oncology Holdings Inc lost $102M in fiscal 2025.
Alx Oncology Holdings Inc
ALXO Nasdaq Pharmaceutical Preparations Financials FY2018βFY2025
Last close Β· Oct 23, 2026
$1.17
1.7%KIRAβs summary AI analyst
Hi! I read Alx Oncology Holdings Incβs latest annual report (fiscal 2025). Here is what stands out:
1 strength 3 to watch
2.Cash and shareholders
See section β- Free cash flow was β$84.4M in fiscal 2025, β of revenue.
- In the last 12 months, insiders bought $5.0M and sold $0.0M of shares on the open market.
3.Financial health
See section β- Alx Oncology Holdings Inc has $33.1M more cash than debt.
- Alx Oncology Holdings Inc passes 1 of 7 financial health tests (Piotroski F-score).
Alx Oncology Holdings Inc in 30 seconds
Good So-so Weak
Weak
Does it make a profit?
β$102M
No. It lost money last year.
Weak
How healthy are the accounts?
1 / 7
Weak. It passes 1 of 7 health tests.
For information
How is the share priced?
β
No P/E: it made no profit over the last four quarters.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Key numbers, fiscal 2025
Market cap
Last close times the latest diluted share count, so it is approximate.
$159M
Oct 23 close
P/E
Last close divided by diluted earnings per share over the last four quarters.
β
On β$1.13 EPS (TTM)
Charts by
Sales and profit
Is it selling more, and how much does it keep?
Revenue and margins
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
FY18
Revenue $2.1M
FY19
Revenue $4.8M
FY20
Revenue $1.2M
FY21
Revenue $0.0M
FY22
Revenue $0.0M
FY23
Revenue β
FY24
Revenue β
FY25
Revenue β
Margins, % of revenue
FY18
Gross β
Operating β662.0%
Net β664.3%
FCF β669.7%
FY19
Gross β
Operating β400.0%
Net β401.2%
FCF β304.5%
FY20
Gross β
Operating β3,694.0%
Net β3,869.7%
FCF β3,242.0%
FY21
Gross β
Operating β
Net β
FCF β
FY22
Gross β
Operating β
Net β
FCF β
FY23
Gross β
Operating β
Net β
FCF β
FY24
Gross β
Operating β
Net β
FCF β
FY25
Gross β
Operating β
Net β
FCF β
Gross
Operating
Net
FCF
Net income and earnings per share
KIRA Β· Alx Oncology Holdings Inc lost $102M in fiscal 2025.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
FY18
Net income β$13.7M
FY19
Net income β$19.2M
FY20
Net income β$45.7M
FY21
Net income β$83.5M
FY22
Net income β$123M
FY23
Net income β$161M
FY24
Net income β$135M
FY25
Net income β$102M
Net income
Q3 '23
Net income β$51.0M
Q4 '23
Net income β$45.5M
Q1 '24
Net income β$35.6M
Q2 '24
Net income β$39.4M
Q3 '24
Net income β$30.7M
Q4 '24
Net income β$29.2M
Q1 '25
Net income β$30.8M
Q2 '25
Net income β$25.9M
Q3 '25
Net income β$22.1M
Q4 '25
Net income β$22.8M
Q1 '26
Net income β$17.9M
Q2 '26
Net income β$18.0M
Diluted EPS
FY18
Diluted EPS β$6.33
FY19
Diluted EPS β$7.56
FY20
Diluted EPS β$2.76
FY21
Diluted EPS β$2.07
FY22
Diluted EPS β$3.03
FY23
Diluted EPS β$3.74
FY24
Diluted EPS β$2.58
FY25
Diluted EPS β$1.90
Diluted EPS
Q3 '23
Diluted EPS β$1.24
Q4 '23
Diluted EPS β$0.92
Q1 '24
Diluted EPS β$0.71
Q2 '24
Diluted EPS β$0.76
Q3 '24
Diluted EPS β$0.58
Q4 '24
Diluted EPS β$0.53
Q1 '25
Diluted EPS β$0.58
Q2 '25
Diluted EPS β$0.49
Q3 '25
Diluted EPS β$0.41
Q4 '25
Diluted EPS β$0.42
Q1 '26
Diluted EPS β$0.17
Q2 '26
Diluted EPS β$0.13
Cash and shareholders
How much cash comes in, and where does it go?
Cash flow
KIRA Β· Free cash flow was β$84.4M in fiscal 2025, β of revenue.
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
FY18
Free cash flow β$13.8M
FY19
Free cash flow β$14.6M
FY20
Free cash flow β$38.3M
FY21
Free cash flow β$68.8M
FY22
Free cash flow β$90.7M
FY23
Free cash flow β$132M
FY24
Free cash flow β$122M
FY25
Free cash flow β$84.4M
Free cash flow
Q3 '23
Free cash flow β$29.9M
Q4 '23
Free cash flow β$39.8M
Q1 '24
Free cash flow β$38.1M
Q2 '24
Free cash flow β$26.7M
Q3 '24
Free cash flow β$25.5M
Q4 '24
Free cash flow β$32.1M
Q1 '25
Free cash flow β$24.7M
Q2 '25
Free cash flow β$23.5M
Q3 '25
Free cash flow β$17.1M
Q4 '25
Free cash flow β$19.0M
Q1 '26
Free cash flow β$18.7M
Q2 '26
Free cash flow β$16.1M
Cash from operations vs capital spending
FY18
Cash from operations β$13.2M
Capital spending $0.7M
FY19
Cash from operations β$14.2M
Capital spending $0.4M
FY20
Cash from operations β$38.3M
Capital spending $0.0M
FY21
Cash from operations β$68.1M
Capital spending $0.7M
FY22
Cash from operations β$89.2M
Capital spending $1.4M
FY23
Cash from operations β$130M
Capital spending $1.3M
FY24
Cash from operations β$122M
Capital spending $0.4M
FY25
Cash from operations β$84.1M
Capital spending $0.2M
Cash from operations
Capital spending
Cash from operations vs capital spending
Q3 '23
Cash from operations β$31.2M
Capital spending β$1.3M
Q4 '23
Cash from operations β$39.7M
Capital spending $0.1M
Q1 '24
Cash from operations β$37.9M
Capital spending $0.1M
Q2 '24
Cash from operations β$26.6M
Capital spending $0.1M
Q3 '24
Cash from operations β$25.4M
Capital spending $0.1M
Q4 '24
Cash from operations β$32.0M
Capital spending $0.1M
Q1 '25
Cash from operations β$24.7M
Capital spending $0.1M
Q2 '25
Cash from operations β$23.4M
Capital spending $0.0M
Q3 '25
Cash from operations β$17.1M
Capital spending $0.1M
Q4 '25
Cash from operations β$19.0M
Capital spending $0.0M
Q1 '26
Cash from operations β$18.6M
Capital spending $0.1M
Q2 '26
Cash from operations β$16.1M
Capital spending $0.0M
Cash from operations
Capital spending
Dividends, buybacks and share count
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
FY18
Dividends β
Buybacks $0.0M
FY19
Dividends β
Buybacks β
FY20
Dividends β
Buybacks β
FY21
Dividends β
Buybacks β
FY22
Dividends β
Buybacks β
FY23
Dividends β
Buybacks β
FY24
Dividends β
Buybacks β
FY25
Dividends β
Buybacks β
Dividends
Buybacks
Diluted shares outstanding (annual)
FY18
Diluted shares 0.00B
FY19
Diluted shares 0.00B
FY20
Diluted shares 0.02B
FY21
Diluted shares 0.04B
FY22
Diluted shares 0.04B
FY23
Diluted shares 0.04B
FY24
Diluted shares 0.05B
FY25
Diluted shares 0.05B
Insider trades
KIRA Β· In the last 12 months, insiders bought $5.0M and sold $0.0M of shares on the open market.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$5.0M
1 insider
Sold, 12 months
$0.0M
3 insiders
Of sales under plans
0%
$0.0M
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Aug 17, 2026 | Jason LettmannChief Executive Officer, Director | Sold | 2,230 | $1.93 | $0.0M | Form 4 |
| Aug 17, 2026 | Shelly WongSVP, Finance and CAO | Sold | 573 | $1.93 | $0.0M | Form 4 |
| Jul 1, 2026 | Shelly WongSVP, Finance and CAO | Sold | 1,404 | $2.04 | $0.0M | Form 4 |
| Mar 19, 2026 | Jason LettmannChief Executive Officer, Director | Sold | 12,311 | $2.17 | $0.0M | Form 4 |
| Mar 19, 2026 | Shelly PintoSVP, Finance and CAO | Sold | 903 | $2.17 | $0.0M | Form 4 |
| Feb 18, 2026 | Shelly PintoSVP, Finance and CAO | Sold | 565 | $2.27 | $0.0M | Form 4 |
| Feb 2, 2026 | Corey S GoodmanDirector, 10% owner | Bought | 3,184,713 | $1.57 | $5.0M | Form 4 |
| Jan 6, 2026 | Shelly PintoSVP, Finance and CAO | Sold | 3,925 | $1.11 | $0.0M | Form 4 |
Financial health
Can it carry its debts, and how well does it use its money?
Balance sheet
KIRA Β· Alx Oncology Holdings Inc has $33.1M more cash than debt.
Cash, debt and the ratios that show how comfortably Alx Oncology Holdings Inc can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
FY18
Cash $8.3M
Debt β
FY19
Cash $9.0M
Debt $5.4M
FY20
Cash $434M
Debt β
FY21
Cash $364M
Debt β
FY22
Cash $266M
Debt $10.9M
FY23
Cash $183M
Debt $12.9M
FY24
Cash $128M
Debt $13.3M
FY25
Cash $44.8M
Debt $11.7M
Cash
Debt
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $364M | $266M | $183M | $128M | $44.8M |
| Debt incl. finance leases | β | $10.9M | $12.9M | $13.3M | $11.7M |
| Debt / equity | β | 0.0x | 0.1x | 0.1x | 0.4x |
| Interest coverage | β6,427.3x | β535.4x | β108.8x | β82.4x | β64.9x |
| Current ratio | 24.0x | 9.6x | 5.2x | 7.3x | 2.1x |
| Quick ratio | 24.0x | 9.6x | 5.2x | 7.3x | 2.1x |
| Total assets | $380M | $306M | $243M | $148M | $59.0M |
| Total liabilities | $17.1M | $43.0M | $52.8M | $34.2M | $33.1M |
| Shareholders' equity | $363M | $263M | $190M | $114M | $26.0M |
| Net debt (β = net cash) | β | β$255M | β$170M | β$114M | β$33.1M |
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
FY18
Return on capital β
Return on equity β
Return on assets β
FY19
Return on capital β
Return on equity β
Return on assets β180.2%
FY20
Return on capital β
Return on equity β25.5%
Return on assets β20.5%
FY21
Return on capital β
Return on equity β21.1%
Return on assets β20.5%
FY22
Return on capital β1,281.3%
Return on equity β39.4%
Return on assets β36.0%
FY23
Return on capital β765.4%
Return on equity β71.0%
Return on assets β58.6%
FY24
Return on capital β
Return on equity β88.9%
Return on assets β69.1%
FY25
Return on capital β
Return on equity β145.7%
Return on assets β98.3%
Return on capital
Return on equity
Return on assets
Piotroski F-score
KIRA Β· Alx Oncology Holdings Inc passes 1 of 7 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β |
| F-score | β / 3 | β / 4 | 3 / 7 | 1 / 7 | 1 / 7 | 1 / 7 | 2 / 7 | 1 / 7 |
| Accruals ratio | β | β46.8% | β3.3% | β3.8% | β10.0% | β11.1% | β6.6% | β17.0% |
| Altman Z'' | β | β38.11 | 77.60 | 25.11 | 5.37 | β3.35 | β11.55 | β48.01 |
All figures
Every number, year by year.
8 years of figures
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $2.1M | $4.8M | $1.2M | $0.0M | $0.0M | β | β | β |
| Research and development | $11.3M | $16.3M | $29.0M | $60.2M | $98.4M | $142M | $116M | $77.0M |
| Operating income | β$13.7M | β$19.2M | β$43.7M | β$83.6M | β$127M | β$170M | β$142M | β$104M |
| Interest expense | β | β | β | $0.0M | $0.2M | $1.6M | $1.7M | $1.6M |
| Pretax income | β$13.7M | β$19.2M | β$45.5M | β$83.5M | β$123M | β$161M | β$135M | β$102M |
| Income tax | $0.0M | $0.0M | $0.2M | β$0.0M | $0.1M | $0.0M | $0.0M | $0.0M |
| Net income | β$13.7M | β$19.2M | β$45.7M | β$83.5M | β$123M | β$161M | β$135M | β$102M |
| Net income to common | β$17.4M | β$23.3M | β$50.9M | β$83.5M | β$123M | β | β | β |
| Diluted EPS | β$6.33 | β$7.56 | β$2.76 | β$2.07 | β$3.03 | β$3.74 | β$2.58 | β$1.90 |
| Diluted shares | 0.00B | 0.00B | 0.02B | 0.04B | 0.04B | 0.04B | 0.05B | 0.05B |
| Cash flow | ||||||||
| Cash from operations | β$13.2M | β$14.2M | β$38.3M | β$68.1M | β$89.2M | β$130M | β$122M | β$84.1M |
| Capital expenditure | $0.7M | $0.4M | $0.0M | $0.7M | $1.4M | $1.3M | $0.4M | $0.2M |
| Free cash flow | β$13.8M | β$14.6M | β$38.3M | β$68.8M | β$90.7M | β$132M | β$122M | β$84.4M |
| Depreciation and amortization | $0.4M | $0.4M | $0.2M | $0.1M | $0.3M | $0.8M | $0.9M | $0.7M |
| Stock-based compensation | $0.3M | $0.3M | $5.4M | $13.9M | $23.8M | $26.3M | $27.1M | $12.6M |
| Share buybacks | $0.0M | β | β | β | β | β | β | β |
| Dividends and buybacks | $0.0M | β | β | β | β | β | β | β |
| Balance sheet | ||||||||
| Cash and short-term investments | $8.3M | $9.0M | $434M | $364M | $266M | $183M | $128M | $44.8M |
| Total debt | β | $5.4M | β | β | $10.6M | $10.6M | $10.6M | $10.2M |
| Finance lease liabilities | β | β | β | $0.7M | $0.3M | $2.3M | $2.7M | $1.6M |
| Current assets | β | $9.8M | $436M | $367M | $271M | $189M | $134M | $50.7M |
| Current liabilities | β | $5.0M | $6.2M | $15.3M | $28.3M | $36.0M | $18.5M | $24.6M |
| Property and equipment, net | β | $0.9M | $0.1M | $0.9M | $3.9M | $3.6M | $2.9M | $1.2M |
| Total assets | β | $10.7M | $436M | $380M | $306M | $243M | $148M | $59.0M |
| Total liabilities | β | $11.0M | $6.2M | $17.1M | $43.0M | $52.8M | $34.2M | $33.1M |
| Shareholders' equity | β$51.8M | β$70.6M | $430M | $363M | $263M | $190M | $114M | $26.0M |
| Margins | ||||||||
| Operating margin | β662.0% | β400.0% | β3,694.0% | β | β | β | β | β |
| EBITDA margin | β641.2% | β391.0% | β3,676.9% | β | β | β | β | β |
| Net margin | β664.3% | β401.2% | β3,869.7% | β | β | β | β | β |
| FCF margin | β669.7% | β304.5% | β3,242.0% | β | β | β | β | β |
| Returns | ||||||||
| Return on capital | β | β | β | β | β1,281.3% | β765.4% | β | β |
| Return on capital employed | β | β337.0% | β10.2% | β22.9% | β45.8% | β82.4% | β110.2% | β301.6% |
| Return on equity | β | β | β25.5% | β21.1% | β39.4% | β71.0% | β88.9% | β145.7% |
| Return on assets | β | β180.2% | β20.5% | β20.5% | β36.0% | β58.6% | β69.1% | β98.3% |
| Return on tangible equity | β | β | β11.9% | β23.0% | β46.9% | β84.8% | β118.7% | β391.4% |
| Growth | ||||||||
| Revenue growth | β | 132.0% | β75.4% | β100.0% | β | β | β | β |
| Share count change | β | 11.8% | 500.9% | 118.1% | 1.0% | 5.6% | 21.4% | 2.8% |
| Financial health | ||||||||
| Debt / equity | β | β | β | β | 0.0x | 0.1x | 0.1x | 0.4x |
| Interest coverage | β | β | β | β6,427.3x | β535.4x | β108.8x | β82.4x | β64.9x |
| Current ratio | β | 2.0x | 70.3x | 24.0x | 9.6x | 5.2x | 7.3x | 2.1x |
| Quick ratio | β | 2.0x | 70.3x | 24.0x | 9.6x | 5.2x | 7.3x | 2.1x |
| Capital allocation | ||||||||
| Capex / revenue | 31.6% | 7.4% | 2.6% | β | β | β | β | β |
| Stock comp / revenue | 13.0% | 6.2% | 459.9% | β | β | β | β | β |
| Quality scores | ||||||||
| Piotroski F-score | β | β | 3.0 | 1.0 | 1.0 | 1.0 | 2.0 | 1.0 |
| Altman Z'' | β | β38.1 | 77.6 | 25.1 | 5.4 | β3.4 | β11.5 | β48.0 |
| Accruals ratio | β | β46.8% | β3.3% | β3.8% | β10.0% | β11.1% | β6.6% | β17.0% |
Source: SEC EDGAR XBRL filings (CIK 0001810182). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.